2008
DOI: 10.1002/hep.22627
|View full text |Cite
|
Sign up to set email alerts
|

Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

17
302
4
4

Year Published

2009
2009
2021
2021

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 343 publications
(327 citation statements)
references
References 39 publications
17
302
4
4
Order By: Relevance
“…There are many potential mechanisms by which PKC␤ either indirectly or directly can affect hepatic CYP7A1 transcription. First, p42/44 MAPK activation has been linked with CYP7A1 suppression by both SHP-dependent and SHP-independent pathways (44,45). One such study has shown that p42/44 MAPK -induced phosphorylation of hepatic SHP at serine 26 stabilizes this protein by inhibiting ubiquitin-proteasomal degradation (45).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…There are many potential mechanisms by which PKC␤ either indirectly or directly can affect hepatic CYP7A1 transcription. First, p42/44 MAPK activation has been linked with CYP7A1 suppression by both SHP-dependent and SHP-independent pathways (44,45). One such study has shown that p42/44 MAPK -induced phosphorylation of hepatic SHP at serine 26 stabilizes this protein by inhibiting ubiquitin-proteasomal degradation (45).…”
Section: Discussionmentioning
confidence: 99%
“…First, p42/44 MAPK activation has been linked with CYP7A1 suppression by both SHP-dependent and SHP-independent pathways (44,45). One such study has shown that p42/44 MAPK -induced phosphorylation of hepatic SHP at serine 26 stabilizes this protein by inhibiting ubiquitin-proteasomal degradation (45). However, lack of a significant change in hepatic SHP content between genotypes argues against involvement of SHP-dependent pathways in CYP7A1 repression.…”
Section: Discussionmentioning
confidence: 99%
“…Fgf15/FGF19 is an endocrine-acting factor that is released in the portal circulation. Binding of Fgf15/FGF19 to its hepatic receptor (complex of Fgfr4 and bKlotho) results in activation of a signaling cascade that causes downregulation of Cyp7a1 and diminished bile salt synthesis [42][43][44] (Fig. 1).…”
Section: Farnesoid X Receptor and Liver Regenerationmentioning
confidence: 99%
“…FGF19 has recently been shown to be present in the human hepatocyte [38], and it is not known whether patients with idiopathic bile acid malabsorption form FGF19 in the liver. We might dare to predict that there are other patients with idiopathic bile acid malabsorption who will prove to be deficient in FGF receptor 4 or do not form the required cofactor, b-klotho.…”
Section: Editorialmentioning
confidence: 99%